Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer
- 338 Downloads
This study assessed the safety, efficacy, and pharmacokinetics of motesanib, a multitargeted small molecule angiogenesis inhibitor, with and without panitumumab, in combination with FOLFIRI or FOLFOX in patients with metastatic colorectal cancer (mCRC).
This open-label, phase 1b, two-part, multicenter study in patients with mCRC and ≤1 prior treatment evaluated escalating doses (50, 75, 100, or 125 mg QD, 75 mg BID) of motesanib with panitumumab and chemotherapy (Part 1) and the target dose of motesanib with chemotherapy (Part 2).
At 17 sites in the USA and Australia, 119 patients were enrolled between December 2004 and February 2010. In Part 1 [motesanib plus panitumumab/FOLFIRI (n = 36) or plus panitumumab/FOLFOX (n = 17)], all motesanib doses tested were tolerated and 125 mg QD was deemed the target dose. Following toxicity results for combination therapy in other trials, panitumumab was withdrawn from the study. Part 2 evaluated motesanib 125 mg with chemotherapy [FOLFIRI (n = 37); FOLFOX (n = 29)]. The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %). The most common adverse events were diarrhea, nausea, fatigue, and hypertension. We observed a low rate of cholecystitis [3 of 119 (2.5 %)], a known adverse event of motesanib and other small molecule VEGF inhibitors.
Motesanib 125 mg QD in combination with FOLFIRI or FOLFOX chemotherapy was tolerated and demonstrated modest efficacy in first-/second-line mCRC.
KeywordsAnti-angiogenic Targeted agent Metastatic colorectal cancer Dose-escalation Motesanib Panitumumab
This work was sponsored by Amgen Inc. The authors would like to thank Yining Ye for statistical support; Bethlyn Sloey, Shubhada Kulkarni, and Bernd Bruenner, all of Amgen Inc., for their contribution to PK sample and data analysis; and Wanda Krall, Ph.D., whose work was funded by Amgen Inc., for assistance in the preparation of this manuscript.
- 1.Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2013) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. GLOBOCAN 2012 v10, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] Lyon, France: International Agency for Research on Cancer. http://globocan.iarc.fr, accessed on 13/12/2013
- 3.NCCN (2014) National Comprehensive Cancer Care Network Clinical Practice Guidelines in Oncology™: colorectal cancer. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Version 2.2015
- 9.Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L et al (2006) AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66:8715–8721CrossRefPubMedGoogle Scholar
- 12.Benjamin RS, Schoffski P, Hartmann JT, Van Oosterom A, Bui BN, Duyster J et al (2011) Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol 68:69–77CrossRefPubMedCentralPubMedGoogle Scholar
- 13.Blumenschein GR Jr, Reckamp K, Stephenson GJ, O’Rourke T, Gladish G, McGreivy J et al (2010) Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 16:279–290CrossRefPubMedGoogle Scholar
- 14.Blumenschein GR Jr, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT et al (2011) A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 22:2057–2067CrossRefPubMedGoogle Scholar
- 15.Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L et al (2011) Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 12:369–376CrossRefPubMedGoogle Scholar
- 16.Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F et al (2012) International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 30:2829–2836CrossRefPubMedGoogle Scholar
- 17.Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664CrossRefPubMedGoogle Scholar
- 19.Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706–4713CrossRefPubMedGoogle Scholar
- 20.Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697–4705CrossRefPubMedGoogle Scholar
- 21.Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR et al (2014) PEAK: A randomized, multicenter phase II study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS Exon 2 metastatic colorectal cancer. J Clin Oncol 32(21):2240–2247. doi: 10.1200/JCO.2013.53.2473 CrossRefPubMedGoogle Scholar
- 27.Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM et al (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25:4557–4561CrossRefPubMedGoogle Scholar
- 28.Van Cutsem E, Bajetta E, Valle J, Kohne CH, Hecht JR, Moore M et al (2011) Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 29:2004–2010CrossRefPubMedGoogle Scholar
- 29.Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL et al (2012) Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol 30:3588–3595CrossRefPubMedGoogle Scholar
- 30.Hecht JR, Trarbach T, Hainsworth JD, Major P, Jager E, Wolff RA et al (2011) Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 29:1997–2003CrossRefPubMedGoogle Scholar
- 35.Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499–3506CrossRefPubMedGoogle Scholar
- 36.Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H et al (2012) Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist 17:1486–1495CrossRefPubMedCentralPubMedGoogle Scholar